Recursion claims that its artificial-intelligence-backed drug discovery platform gets smarter each time it pinpoints a new drug candidate—which is why, even with several of those candidates already in ...
Anthropic's research suggests AI is increasingly used to develop and improve new AI systems, with Claude now writing over 80% ...
The market is viewing NVIDIA's decision to keep its 7.7 million share stake in Recursion while divesting from other AI holdings as a significant strategic move. This decision indicates NVIDIA's ...
Following piloted FX activity, Krytheon advances toward point-of-sale deployment across a 23-country carrier and its ...
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on May 26, 2026, the Compensation Committee of Recursion's Board of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results